Novartis

Showing of 1 - 20 from 61 results
Novartis - Total results - 61
New hormone-based breast cancer drug found to boost survival rates dramatically
science

New hormone-based breast cancer drug found to boost survival rates dramatically

Researchers are interested in exploring whether the drug could help nip cancer in the bud at early stages.

FDA approves $2.1 million Novartis' 'Zolgensma', makes it the costliest drug ever
science

FDA approves $2.1 million Novartis' 'Zolgensma', makes it the costliest drug ever

Zolgensma, a one-time drug for spinal muscular atrophy, affects 1 in 10,000 children and mostly leads to death.

Sun Pharma acquires Japan's Pola Pharma; firm eyes to expand global presence in dermatology segment
Business

Sun Pharma acquires Japan's Pola Pharma; firm eyes to expand global presence in dermatology segment

The acquisition of 100 percent shares of Pola Pharma Inc Japan by the company's wholly owned subsidiary has been concluded, Sun Pharma said in a BSE filing.

GSK Consumer Healthcare says it is considering potential transaction of nutrition business; Unilever confirms development
Business

GSK Consumer Healthcare says it is considering potential transaction of nutrition business; Unilever confirms development

Hindustan Unilever, the Indian arm of Unilever, confirmed that the company was in the race to acquire GlaxoSmithKline Plc's consumer healthcare nutrition products

GSK seeks mid-September bids for $4 billion Indian Horlicks unit, say sources
Business

GSK seeks mid-September bids for $4 billion Indian Horlicks unit, say sources

GSK started a strategic review of Horlicks - a malt-based drink brand popular in India – and some smaller products, after buying Novartis out of their consumer healthcare venture for $13 billion in March.

GSK to sell Horlicks to fund $13 bn Novartis deal; Nestle, Kraft, Unilever likely suitors, say sources
Business

GSK to sell Horlicks to fund $13 bn Novartis deal; Nestle, Kraft, Unilever likely suitors, say sources

GSK has started a strategic review of Horlicks - a malt-based drink brand popular in India – and some of its smaller products, after buying Novartis out of their consumer healthcare venture for $13 billion on Tuesday.

Novartis CEO Narasimhan rehauls co leadership as operations president Andre Wyss exits
Business

Novartis CEO Narasimhan rehauls co leadership as operations president Andre Wyss exits

Novartis’ new Chief Executive Vas Narasimhan is remaking the Swiss drugmaker’s leadership as operations president Andre Wyss exits

ISB sees 39% rise in campus placements with 1,113 offers, average salary at Rs 22 lakh
Business

ISB sees 39% rise in campus placements with 1,113 offers, average salary at Rs 22 lakh

Over 70 offers were made to ISB students for leadership roles by leading corporates including Aditya Birla Group, Citibank, Yes Bank, Philips India Ltd, Tech Mahindra, MAX, Mytrah Energy and Genpact.

Google to bet on Euro biotech company to deliver life-changing drugs
News & Analysis

Google to bet on Euro biotech company to deliver life-changing drugs

The move shows Google pumping cash into global medical research, seeding what it believes will become a core long-term healthcare business.

Novartis backs out of human testing of Google autofocus contact lens in 2016
News & Analysis

Novartis backs out of human testing of Google autofocus contact lens in 2016

Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is "progressing steadily."

Sun Pharma inks distribution alliance with Mitsubishi Tanabe for 14 brands
Business

Sun Pharma inks distribution alliance with Mitsubishi Tanabe for 14 brands

These 14 prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma K.K. to Sun Pharma's subsidiary in Japan beginning October 2016

Prices of cancer, diabetes, blood pressure drugs slashed by 25%
Business

Prices of cancer, diabetes, blood pressure drugs slashed by 25%

Prices of 56 important drugs used in treatment of cancer, diabetes, bacterial infections and blood pressure have been capped by the government thereby reducing the cost by an average of around 25 percent.

Prices of 56 drugs to come down; NPPA fixes ceiling rates
Business

Prices of 56 drugs to come down; NPPA fixes ceiling rates

Prices may come down of 56 important medicines used in treatment of cancer, diabetes, bacterial infections and high blood pressure, with the government fixing their ceiling prices under the drug pricing control mechanism.

PM invites Swiss business leaders to invest in India
Business

PM invites Swiss business leaders to invest in India

Seeking to create two or three Switzerlands within India, Prime Minister Narendra Modi today courted Swiss business leaders to boost domestic manufacturing and skill development.

Warning letters for pharma cos galore: Now Cadila Healthcare faces USFDA heat, stock tanks 16%
Business

Warning letters for pharma cos galore: Now Cadila Healthcare faces USFDA heat, stock tanks 16%

The Ahmedabad-headquartered company received a warning letter for its Moraiya formulation facility and Ahmedabad API facility

India needs predictable IPR regime, says Novartis
Business

India needs predictable IPR regime, says Novartis

If the whole data regulatory process becomes predictable in the long run, it makes investment in the country more sustainable, said Novartis Pharma AG, Global Head of Development, Established Medicines Franchise, Lutz Hegemann.

Google granted patent to make contact lenses
News & Analysis

Google granted patent to make contact lenses

This week the US patent authorities granted Google its patent to make contact lenses.

Natco Pharma gains 4.5% after filing ANDA with USFDA
Business

Natco Pharma gains 4.5% after filing ANDA with USFDA

Natco Pharma has filed new product applications with the US health regulator for generic version of drugs used in the treatment of nervous system disease and cancer.

Delhi HC bars Cipla from selling cheaper copy of Novartis respiratory drug
Business

Delhi HC bars Cipla from selling cheaper copy of Novartis respiratory drug

Cipla, India's fourth-largest generic drugmaker by revenue, had launched its copy of Onbrez in New Delhi in October last year at a fifth of the original drug's price, citing urgent unmet need in India.